Cadila Healthcare rose 1.59% to Rs 1499 at 14:11 IST on BSE after consolidated net profit rose 51.59% to Rs 281.91 crore on 16.72% increase in total income to Rs 2199.47 crore in Q3 December 2014 over Q3 December 2013.
The result was announced during trading hours today, 10 February 2015.
Meanwhile, the BSE Sensex was down 158.38 points, or 0.56%, to 28,069.01.
On BSE, so far 21,000 shares were traded in the counter, compared with an average volume of 10,521 shares in the past one quarter.
The stock hit a high of Rs 1,540 and a low of Rs 1,475 so far during the day. The stock hit a record high of Rs 1,760 on 11 November 2014. The stock hit a 52-week low of Rs 872.55 on 19 May 2014.
The stock had underperformed the market over the past one month till 9 February 2015, falling 12.54% compared with 2.80% rise in the Sensex. The scrip had also underperformed the market in past one quarter, falling 0.97% as against Sensex's 1.29% rise.
The large-cap company has an equity capital of Rs 102.37 crore. Face value per share is Rs 5.
During the quarter, the company's business in the US registered a growth of 42% and emerging markets business grew by 23%. During the quarter, the company filed 5 additional ANDAs (Abbreviated New Drug Application) with the US Food and Drug Administration (US FDA) taking the cumulative ANDA filings to 255, Cadila Healthcare said in a statement.
During the quarter, the company launched Exemptia, the world's first biosimilar for Adalimumab, the largest selling therapy worldwide for inflammatory arthritis. Exemptia is given as a 40 milligram subcutaneous injection once every alternate week. The therapy is currently marketed by Zydus Biovation - a new division launched to exclusively market this ground breaking therapy, the company said.
The group's R&D (research and development) pipeline which comprises 25 biologics (including novel biologics), is being developed to treat auto immune disorders like arthritis, cancer, infertility and stroke, the company added.
Cadila Healthcare is a fully integrated, global healthcare provider, with strengths all along the pharmaceutical value chain. With a core competence in the field of healthcare, the company provides total healthcare solutions ranging from formulations, active pharmaceutical ingredients and animal healthcare products to wellness products.
Powered by Capital Market - Live News
